Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1930 1
1934 1
1939 1
1941 1
1944 1
1951 2
1952 2
1953 1
1954 1
1955 1
1956 1
1957 1
1958 1
1961 3
1963 2
1964 3
1965 2
1972 1
1973 1
1974 1
1975 1
1976 1
1977 3
1978 2
1980 2
1983 1
1984 6
1985 4
1986 3
1987 4
1989 4
1990 1
1991 1
1992 6
1993 2
1994 3
1996 5
1997 10
1998 16
1999 8
2000 16
2001 9
2002 19
2003 14
2004 16
2005 21
2006 19
2007 12
2008 15
2009 21
2010 27
2011 23
2012 24
2013 35
2014 27
2015 25
2016 19
2017 25
2018 25
2019 29
2020 27
2021 28
2022 22
2023 6
Text availability
Article attribute
Article type
Publication date

Search Results

567 results
Results by year
Filters applied: . Clear all
Page 1
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Pal SK, et al. Among authors: curran d. J Clin Oncol. 2021 Nov 20;39(33):3725-3736. doi: 10.1200/JCO.21.00939. Epub 2021 Sep 7. J Clin Oncol. 2021. PMID: 34491815 Free PMC article. Clinical Trial.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Agarwal N, et al. Among authors: curran d. Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690072 Clinical Trial.
Burden-of-illness vaccine efficacy.
Callegaro A, Curran D, Matthews S. Callegaro A, et al. Among authors: curran d. Pharm Stat. 2020 Sep;19(5):636-645. doi: 10.1002/pst.2020. Epub 2020 Mar 27. Pharm Stat. 2020. PMID: 32220002 Free PMC article.
Emerging anticoagulants.
Kennedy B, Gargoum FS, Kennedy L, Khan F, Curran DR, O'Connor TM. Kennedy B, et al. Among authors: curran dr. Curr Med Chem. 2012;19(20):3388-416. doi: 10.2174/092986712801215847. Curr Med Chem. 2012. PMID: 22680641 Review.
The electron is a catalyst.
Studer A, Curran DP. Studer A, et al. Among authors: curran dp. Nat Chem. 2014 Sep;6(9):765-73. doi: 10.1038/nchem.2031. Nat Chem. 2014. PMID: 25143210 Review.
Meta-Regression of Herpes Zoster Incidence Worldwide.
Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, Yawn BP. Curran D, et al. Infect Dis Ther. 2022 Feb;11(1):389-403. doi: 10.1007/s40121-021-00567-8. Epub 2021 Dec 7. Infect Dis Ther. 2022. PMID: 34874546 Free PMC article.
567 results